Table listing all the major pharma mergers, acquisitions and collaborations in the past month
This table lists all the major pharma collaborations, acquisitions and mergers agreed during June 2013.
For an indepth analysis of these deals, read 'Pharma deals during June 2013'
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
Pfizer (Wyeth) + Takeda / Teva + Sun Pharmaceutical |
Patent settlement |
Infringement of Protonix patent | 2,150 |
Pearl Therapeutics / AstraZeneca |
Acquisition |
Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III) | 1,150 |
Conceptus / Bayer | Acquisition | Bayer acquires >90 per cent shares includes the product Essure, for non-surgical permanent birth control (marketed) | 1,100 |
Merck / Aspen | Acquisition | Aspen acquires Merck drugs/ manufacturing business | 1,000 |
Aragon Pharmaceuticals / J&J | Acquisition | Includes ARN 509 (second generation androgen receptor signalling inhibitor) for castration-resistant prostate cancer (phase II) | 1,000 |
MorphoSys / Celgene |
Strategic collaboration |
Joint development and co-promotion of MOR 202 in multiple myeloma (phase I/II) | 818 |
CytomX / Pfizer | Collaboration and exclusive licence to selected PDCs | Collaboration for Probody Drug conjugates (PDCs) in oncology (platform) | 635 |
MorphoSys / GSK | Licence to develop and commercialise | MOR 103 (HuCA-derived MAb against GM-CSF), for mild to moderate RA (phase I/II) | 580 |
Seattle Genetics / Bayer HealthCare | Collaboration for development and commmercialisation | Auristatin based antibody-drug conjugate (ADC) technology for certain oncology targets (platform) | 520 |
Cytokinetics / Astellas | Exclusive licence to develop and commercialise | Collaboration for therapies associated with muscle weakness and rights to CK 2127107 (phase I) for certain indications; | 490 |
Immunocore / Genentech | Research collaboration and licence | Discovery and development of multiple targets using Immunocore's ImmTAC technology (platform) | 320+ |
Medicines360 / Actavis* | Licence | US commercial rights to LNG20 Intrauterine Device (IUD) (phase III) | 175 |
MicroDose Therapeutx / Teva | Acquisition | Acquisition of inhalation technology including MDT-637 for RSV (phase II) | 165 |
Novartis / Questcor* | Development rights | Rights to develop Synacthen (tetracosactide, melanocortin receptor agonist) and Synacthen Depot (approved in Europe for autoimmune & inflammatory conditions) | 135 |
Fera / Perrigo | Product portfolio acquisition | Ophthalmic sterile ointment and solution product portfolio | 129 |
Cytokinetics / Amgen** | Extension of existing licence to Japan | Small molecules to activate heart muscle, including omecamtiv mecarbil (phase II) | 75 |
Taiwan Liposome Company / SciClone Pharmaceuticals*** | Exclusive licence | Commercialisation of ProFlow (lipid emulsion-based formulation of alprostadil) for peripheral arterial disease (approved Taiwan) | 39.5 |
BioLineRx / Jiangsu Chia-tai Tianqing Pharmaceutical (CTTQ)† | Collaboration and licence | BL8030, second generation protease inhibitor in development for Hepatitis C (preclinical) |
30 |
Isconova / Novavax | Acquisition | Proprietary vaccine adjuvant technology | 30 |
Unless noted, transactions are for global rights
* US only
** Japan only
*** China, Hong Kong and Macau
† China and Hong Kong
Wave combine scientific, medical and brand expertise to deliver clinically focused programmes that are trusted by HCPs, drive better patient...